Cisplatin, doxorubicin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma
Cancer Treatment Reports
R P WhiteheadP P Carbone
Abstract
A total of 43 patients with non-small cell carcinoma from a small preliminary trial and a larger in-house study were evaluated after treatment with cisplatin (50 mg/m2), doxorubicin (50 mg/m2), cyclophosphamide (300 mg/m2), and vincristine (1.4 mg/m2), all given iv on Day 1, and lomustine (50 mg/m2) given orally on Day 1. The response rate in the larger trial was 9%, with a 95% confidence interval of 2%-24%. For the combined group of all patients, median survival was 200 days, with a 95% confidence interval of 115-229 days. Hematologic toxicity and nausea and vomiting were moderate to severe and there were two treatment-related deaths. This combination drug regimen appears to have no advantages over other, less toxic regimens in the treatment of non-small cell bronchogenic carcinoma.
Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.